Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0GP8Q
|
|||
| Drug Name |
Risankizumab
|
|||
| Indication | Plaque psoriasis [ICD-11: EA90.0; ICD-10: L40.0; ICD-9: 696] | Approved | [1] | |
| Psoriatic arthritis [ICD-11: FA21; ICD-9: 696] | Phase 2 | [2] | ||
| Company |
AbbVie North Chicago, IL Boehringer Ingelheim Pharmaceuticals Ridgefield, CT
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.